Veeva Systems Inc - Class A NYSE:VEEV Price, Chart, News & Insight

UCB Selects Veeva Vault CRM for Global Commercial Operations

Veeva Systems (NYSE: VEEV) said UCB has selected Veeva Vault CRM as its global customer engagement platform.

Vault CRM is designed specifically for life sciences and combines CRM capabilities with industry-focused AI to support commercial execution, product launches and customer engagement.

UCB said the platform will provide a scalable technology foundation for its commercial operations worldwide.

Vault CRM is part of Veeva’s broader CRM Suite, which includes agentic capabilities such as Agentic Call Report to help commercial teams identify treatment barriers and generate customer insights.

The deal expands Veeva’s adoption among large pharmaceutical companies and reinforces its position in life sciences commercial technology.

💬

WS Investor 11-04-26

Veeva Basics Gains Traction With More Than 175 Emerging Biotech Customers

Veeva Systems (NYSE: VEEV) said more than 175 emerging biotechnology companies are now using Veeva Basics, its pre-configured application suite designed to help smaller life sciences companies establish scalable technology infrastructure early in the drug-development process.

The platform includes applications across clinical, regulatory, quality, medical and commercial functions, with deployment designed to take weeks rather than requiring lengthy custom implementations. Veeva said the approach allows biotechs to standardize operations while reducing IT complexity and supporting future growth.

One use case highlighted by the company is regulatory publishing. Veeva Submissions Publishing Basics allows biotech companies to bring submission preparation and health-authority interactions in-house rather than relying entirely on outsourced providers, giving teams greater control over regulatory timelines and processes.

Whitehawk Therapeutics said Veeva Basics helped it replace paper-based processes without requiring a dedicated IT team or extensive customization. Structure Therapeutics similarly said bringing submission publishing in-house improved quality control and accelerated regulatory timelines.

The offering is built on Veeva’s Vault Platform, allowing customers to expand their technology infrastructure as they progress from early-stage development toward commercialization.

The milestone highlights Veeva’s growing penetration among smaller biotech companies, extending its life sciences cloud strategy beyond large pharmaceutical customers and into earlier-stage drug developers.

💬

Global Finance News 10-07-26

Veeva DQS Processes Data From More Than 1 Million Clinical Trial Subjects

Veeva Systems (NYSE: VEEV) said its Data Quality System has now aggregated and cleaned clinical trial data for more than 1 million subjects across over 1,000 studies.

The platform has generated more than 500,000 automated queries, helping sponsors and research sites reduce the time and manual effort required for data reconciliation and preparation of analysis-ready datasets.

Veeva DQS automates clinical data workflows, supports risk-based quality management and uses AI to classify study data based on its purpose and criticality. The system can also integrate with Veeva CTMS to flag changes such as protocol deviations and help teams track key risk indicators.

The company said the growing volume and complexity of clinical trial data are increasing demand for automated data management tools that can accelerate study reviews and regulatory submissions.

Veeva also recently introduced its Study Builder Agent, which can configure Veeva EDC and DQS directly from a clinical study protocol, further expanding the company’s use of AI across life sciences software workflows.

💬

The Investor 10-06-26

Servier Adopts Veeva OpenData Across More Than 80 Countries to Support AI Expansion

Veeva Systems announced that French pharmaceutical company Servier is standardizing customer reference data across more than 80 countries using Veeva OpenData, creating a unified data foundation intended to support broader adoption of artificial intelligence.

The deployment builds on Servier’s existing use of Veeva Link Key People and is designed to harmonize customer data across markets, reduce fragmentation and give commercial and medical teams more consistent access to healthcare professional information.

Servier said the initiative will create a globally unified semantic layer and improve connectivity between OpenData and Veeva Link, helping affiliates identify and engage the right healthcare professionals more efficiently.

Veeva OpenData is part of Veeva Data Cloud, which also includes Veeva Link and Veeva Compass. The platform is designed to centralize customer reference data and provide a more standardized foundation for analytics and AI applications.

The agreement reflects the growing importance of data quality and consistency as life sciences companies seek to scale AI across commercial, medical and operational workflows.

💬

The Investor 09-30-26

Veeva Launches AI Study Builder Agent to Configure Clinical Studies in as Little as One Day

Veeva Systems (NYSE: VEEV) announced Veeva Study Builder Agent, a new AI solution designed to configure clinical studies directly from a study protocol, potentially reducing study-build timelines to as little as one day.

The agent configures Veeva EDC forms, visits and edit-check rules, as well as CQL-based listings in Veeva DQS. It also automates testing and test-data generation. By reusing an organization’s existing standards and leveraging the CDISC Unified Study Definitions Model, Veeva said the system can produce faster, more consistent and audit-ready study builds.

Study Builder Agent is intended to reduce manual configuration work while limiting deviations from established clinical-data standards. Veeva said the product is part of its broader strategy to simplify, standardize and connect clinical trial operations through AI-driven automation.

The solution is planned for early adopter availability in December 2026, will be included with Veeva EDC at no additional license cost, and will be delivered as a Claude Cowork plugin through a Veeva-managed GitHub repository.

💬

Global Finance News 09-25-26

Amgen Selects Veeva Vault CRM for Global Deployment

Veeva Systems (NYSE: VEEV) announced that Amgen plans to deploy Veeva Vault CRM globally, expanding a technology partnership between the two companies that has lasted for more than a decade.

Amgen will use Vault CRM as part of its commercial infrastructure to support the global launch and delivery of new therapies. The company said the platform should help it operate with greater speed and agility as it brings medicines to patients worldwide.

Vault CRM is part of Veeva’s broader Vault CRM Suite, which is designed specifically for life sciences companies and increasingly incorporates agentic AI into commercial workflows. Features include Agentic Call Report, which can generate commercial evidence and help identify potential barriers affecting treatment adoption.

The Amgen win represents a significant enterprise deployment for Veeva and reinforces its position in life-sciences CRM as pharmaceutical companies increasingly integrate AI agents, industry-specific data and automation into their commercial operations.

💬

The Investor 09-15-26

Veeva Introduces Falcon Safety AI Platform to Automate Drug Safety Operations

Veeva Systems (NYSE: VEEV) announced Tuesday Veeva Falcon Safety, a new agentic AI product designed to automate and streamline pharmacovigilance operations for biopharmaceutical companies.

Falcon Safety will support adverse-event intake, case processing and follow-up, with the goal of reducing operating costs and processing times while maintaining regulatory compliance. The product is part of Veeva AI, the company’s portfolio of industry-specific artificial intelligence solutions for life sciences.

Importantly, Falcon Safety will not be limited to customers using Veeva’s own Safety platform. The product is designed to work with any E2B-compliant safety system, including competing platforms such as Oracle Argus and ArisGlobal LifeSphere MultiVigilance, and across different adverse-event intake channels.

That interoperability could significantly expand Falcon Safety’s addressable market by allowing pharmaceutical companies to adopt Veeva’s AI capabilities without replacing their existing pharmacovigilance infrastructure.

The launch also demonstrates how Veeva is extending AI deeper into specialized, highly regulated life-sciences workflows, where automation can potentially generate meaningful productivity improvements. Falcon Safety is scheduled to become available to early adopters in November 2026.

💬

WS Investor 09-01-26

Veeva Systems Jumps 8% Premarket as AI Momentum and Strong Q2 Results Lift Outlook

Veeva Systems (NYSE: VEEV) shares are up about 8% in premarket trading after the life sciences software company reported fiscal second-quarter results above its guidance across all key metrics and raised its full-year outlook.

Revenue increased 18% year over year to $928 million, while subscription revenue rose 16% to $766.8 million. Profitability grew even faster, with GAAP operating income jumping 40% to $275 million. Non-GAAP EPS increased to $2.35 from $1.99 a year earlier.

AI and Vault CRM strengthen growth story

Investor enthusiasm also appears tied to Veeva's accelerating AI strategy. Vault CRM recorded its best quarter ever, while the company said development of its Veeva Falcon agentic AI platform is progressing rapidly. Falcon currently has five early adopters and remains on track for initial deployments this year.

Vault CRM adoption continues to expand, with more than 180 customers live and commitments from 12 of the world's top 20 biopharma companies.

Management said its full-year outlook improved across the board. Veeva now expects FY2027 revenue of $3.682 billion-$3.687 billion, non-GAAP operating income of approximately $1.64 billion and non-GAAP EPS of about $9.21.

The 8% premarket rally appears driven by the combination of better-than-guided results, strong subscription growth, expanding margins and growing evidence that Veeva's AI products could become an important new growth engine within its already strong life sciences software franchise.

💬

European Investor 08-27-26

Veeva Systems Stock Rises 3.1% as Barclays Raises Price Target to $275

Veeva Systems (NYSE: VEEV) shares are up 3.1% after Barclays raised its price target on the cloud software company, providing a positive catalyst as the firm maintained its Overweight rating.

Barclays analyst Saket Kalia increased the price target for Veeva Systems from $235 to $275. With Veeva trading around $245.65, the new target implies approximately 12% upside.

Why the Barclays Target Increase Is Positive for Veeva

The size of the revision is notable. Barclays lifted its target by $40, or roughly 17%, while retaining its bullish Overweight recommendation. The new $275 target is also comfortably above the stock's price in the report, indicating that Barclays continues to see additional upside even after today's 3.1% gain.

Veeva occupies a distinctive position within the enterprise software sector because of its specialization in cloud applications for the life sciences industry. Its products support pharmaceutical and biotechnology companies across areas including clinical development, regulatory processes, quality management, safety, medical affairs and commercial operations.

This vertical specialization creates a relatively strong competitive position. Life sciences customers operate in highly regulated environments, making industry-specific software, data management and regulatory capabilities particularly important. Once these systems become embedded in customers' workflows, switching providers can also become operationally complex.

## AI and Life Sciences Software Provide Longer-Term Growth Opportunities

Veeva is also positioned at the intersection of enterprise software, healthcare technology and the broader digital transformation of pharmaceutical development. Increasing use of data analytics and AI across drug development and commercial operations could expand demand for integrated cloud platforms capable of managing increasingly complex life-sciences workflows and data.

Unlike more general enterprise software companies, Veeva's concentration on life sciences gives investors relatively direct exposure to technology spending within pharmaceutical and biotechnology companies.

Barclays' decision to raise its target from $235 to $275 while maintaining an Overweight rating reinforces that growth thesis. With the new target implying about 12% upside from $245.65, the analyst action appears to be a key factor supporting Veeva Systems shares today.

💬

European Investor 08-18-26

Veeva Systems Expands Lilly Partnership With Global Vault CRM Rollout

Veeva Systems (NYSE: VEEV) announced that Eli Lilly and Company has selected Veeva Vault CRM for deployment across its global operations, expanding the companies’ existing strategic relationship.

Vault CRM is part of Veeva’s CRM Suite and is designed to support an AI-enabled commercial model for life sciences companies. The platform combines CRM applications, data and agentic AI capabilities aimed at improving interactions between pharmaceutical companies and healthcare professionals.

Lilly said the transition to Vault CRM will support its efforts to bring new medicines to more patients worldwide.

The selection represents a significant customer win for Veeva given Lilly’s scale as a global pharmaceutical company. It also reinforces Veeva’s position in life-sciences cloud software as the company expands AI capabilities across its commercial platform.

💬

The Investor 08-11-26

NYSE:VEEVFollow

NYSE:VEEV